1
|
The birth, decline, and contemporary re-emergence of endovascular brachytherapy for prevention of in-stent restenosis. Brachytherapy 2020; 20:485-493. [PMID: 33132069 DOI: 10.1016/j.brachy.2020.09.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Revised: 09/13/2020] [Accepted: 09/18/2020] [Indexed: 01/08/2023]
Abstract
Despite the advent of drug-eluting stents and dual antiplatelet therapy in the interventional management of cardiovascular disease, restenosis rates remain high with significant sequelae. Endovascular brachytherapy-popular in the 1990s and early 2000s-has recently resurfaced as a cost-effective treatment option. In this work, we outline the history of endovascular brachytherapy starting with its earliest promise in the 1990s. We discuss the development of drug-eluting stents and dual antiplatelet strategies and their impact on the perceived benefit of endovascular brachytherapy. For the contemporary era, we propose novel roles for endovascular brachytherapy in complex coronary artery disease and in high-risk patients managed with drug-eluting stents. We discuss the impetus for reducing the requirement and duration of dual antiplatelet therapy using endovascular brachytherapy. We also review innovative opportunities for endovascular brachytherapy after bare-metal stent placement in both coronary and noncoronary territories and offer economic arguments in favor of endovascular brachytherapy. Trials of endovascular brachytherapy in these regimes are merited.
Collapse
|
2
|
Thalhammer C, Alvarez E, Husmann M, Staub D, Kaspar M, Aschwanden M, Amann-Vesti BR. Long term follow-up after endovascular brachytherapy of femoro-popliteal arteries. Clin Hemorheol Microcirc 2015; 61:251-7. [PMID: 26410876 DOI: 10.3233/ch-151997] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
To perform a long term follow-up after endovascular brachytherapy (EVBT) and balloon angioplasty (PTA) regarding vessel patency and diameter. EVBT had been successfully used to decrease restenosis in short term, but long term data are lacking. Participants of a randomized study comparing EVBT and balloon angioplasty alone were invited for follow-up examination ten years after intervention. Using a standardized protocol measurement of the patency and vessel diameter was performed of femoral and popliteal arteries. 44 patients were included, 21 had been treated with EVBT and 23 had received PTA alone. Target lesion patency was similar between the two groups (90.5% vs. 87.0%). Vessel diameter of the target lesion was significantly greater in the EVBT group (6.4 mm, range 3.9-9.9) compared to the controls (5.0 mm, range 3.1-7.4; p = 0.002). Ten years after EVBT of femoro-popliteal arteries vessel diameter is significantly increased whereas patency rate is not different compared to angioplasty alone.
Collapse
Affiliation(s)
- Christoph Thalhammer
- University Hospital Zurich, Clinic for Angiology and University Zurich, Zurich, Switzerland
| | - Elena Alvarez
- University Hospital Zurich, Clinic for Angiology and University Zurich, Zurich, Switzerland
| | - Marc Husmann
- University Hospital Zurich, Clinic for Angiology and University Zurich, Zurich, Switzerland
| | - Daniel Staub
- University Hospital Basel, Clinic for Angiology Basel, Switzerland
| | - Mathias Kaspar
- University Hospital Basel, Clinic for Angiology Basel, Switzerland
| | | | - Beatrice R Amann-Vesti
- University Hospital Zurich, Clinic for Angiology and University Zurich, Zurich, Switzerland
| |
Collapse
|
3
|
HDR brachytherapy: an option for preventing nonmalignant obstruction in patients after lung transplantation. Strahlenther Onkol 2012; 188:1085-90. [DOI: 10.1007/s00066-012-0215-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2012] [Accepted: 07/16/2012] [Indexed: 10/27/2022]
|
4
|
Sadeghi M, Kiavar O, Hosseini SH, Fatehi R, Tenreiro C. Cyclotron production and parameters calculation of 48V Nitinol stent for renal arteries in brachytherapy. J Radioanal Nucl Chem 2011. [DOI: 10.1007/s10967-011-1138-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Arbabi A, Sadeghi M, Joharifard M. Irradiation and dosimetry of Nitinol stent for renal artery brachytherapy. Appl Radiat Isot 2008; 67:129-32. [PMID: 18760611 DOI: 10.1016/j.apradiso.2008.07.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2008] [Accepted: 07/15/2008] [Indexed: 11/28/2022]
Abstract
This study was conducted to assess the suitability of (48)V radioactive stent for use in renal artery brachytherapy. A nickel-titanium alloy Nitinol stent was irradiated over the proton energy range of up to 8.5 MeV, to obtain (48)V. The depth dose distribution analysis of the activated stent was done with TLD-700 GR in a Perspex phantom. We investigated a unique mixed gamma/beta brachytherapy source of (48)V. For a 10mm outer-diameter (48)V stent, the average measured dose rate to vessel was 37 mGy/h. The dosimetry results of the (48)V stent suggest that the stent is suitable for use in renal artery brachytherapy.
Collapse
Affiliation(s)
- Azim Arbabi
- Science and Research Campus, Islamic Azad University, P.O. Box 14515-775, Tehran, Iran
| | | | | |
Collapse
|
6
|
Park JS, Oh JH, Kim DY, Park YK, Park SJ, Kim SJ. Effects of intraluminal irradiation with Holmium-166 for TIPS stenosis: experimental study in a swine model. Korean J Radiol 2007; 8:127-35. [PMID: 17420630 PMCID: PMC2626774 DOI: 10.3348/kjr.2007.8.2.127] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
OBJECTIVE We wanted to evaluate the effectiveness of intraluminal irradiation with Holmium-166 ((166)Ho) for reducing the pseudointimal hyperplasia (PIH) in the transjugular intrahepatic portosystemic shunt (TIPS) tract in a swine model. MATERIALS AND METHODS TIPS was performed in 12 domestic pigs, after the creation of portal hypertension by intraportal injection of a mixture of N-butyl-2-cyanoacrylate (NBCA) and lipiodol. Five pigs first underwent intraluminal irradiation (30 Gy) in the parenchymal tract with using a (166)Ho solution-filled balloon catheter, and this was followed by the placement of a nitinol stent in the TIPS tract. For the seven control pigs, the balloon was filled with saline and contrast media mixture. Two weeks later, follow-up portography and histological analysis were performed. RESULTS TIPS was successfully performed in all twelve pigs with achieving artificially induced portal hypertension. Portography performed two weeks after TIPS showed the patent tracts in the TIPS tracts that were irradiated with (166)Ho (5/5, 100%), whereas either completely (5/6, 83.3%) or partially (1/6, 16.7%) occluded TIPS were seen in the seven pigs of the nonirradiated control group, except in one pig that experienced periprocedural death due to bleeding. Histological analysis showed a statistically significant difference for the maximal PIH (irradiated: 32.8%, nonirradiated: 76.0%, p < 0.001) between the two groups. CONCLUSION Intraluminal irradiation with 30 Gy of (166)Ho for TIPS significantly improved the TIPS patency in a swine model of portal hypertension during a 2-week period of follow-up.
Collapse
Affiliation(s)
- Ji Seon Park
- Department of Diagnostic Radiology, Kyung Hee University Medical Center, Seoul 130-702, Korea
| | - Joo Hyeong Oh
- Department of Diagnostic Radiology, Kyung Hee University Medical Center, Seoul 130-702, Korea
| | - Deog Yoon Kim
- Department of Nuclear Medicine, Kyung Hee University Medical Center, Seoul 130-702, Korea
| | - Yong Koo Park
- Department of Pathology, Kyung Hee University Medical Center, Seoul 130-702, Korea
| | - Sang Joon Park
- Department of Diagnostic Radiology, Kang Dong Sacred Heart Hospital, Hallym University, Seoul 134-010, Korea
| | - Soo Joong Kim
- Department of Cardiology, Kyung Hee University Medical Center, Seoul 130-702, Korea
| |
Collapse
|
7
|
Xu Y, Jagtap MR, Garland T, Ying J, McGarry RC, Mendonca MS, McLennan G. Iododeoxyuridine uptake in proliferating smooth muscle cells in vitro. J Vasc Interv Radiol 2007; 18:73-8. [PMID: 17296707 DOI: 10.1016/j.jvir.2006.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
PURPOSE Iododeoxyuridine (IUdR) is a halogenated pyrimidine recognized as the thymidine substitute in DNA. When labeled with iodine 125, IUdR can be used as a carrier to incorporate the isotope into DNA and target the dividing cells. The purpose of this study was to assess the maximum uptake of IUdR by proliferating smooth muscle cells (SMCs) in vitro to determine the optimal concentration to be administered in an in vivo experiment. The long-term goal is to use radioactive IUdR to inhibit SMC proliferation and recurrent stenosis of arteries after balloon angioplasty in vivo. MATERIALS AND METHODS Porcine vascular SMCs were cultured in 5% fetal bovine serum medium and stimulated to proliferate by adding a medium containing 10% fetal bovine serum and insulin. IUdR was added to the proliferating SMCs at concentrations of 5, 10, 20, 30, and 40 micro mol/L on days 1, 3, 5, and 7 of incubation. One group of cells--the control group--did not receive IUdR. The SMCs were harvested and double-stained with an anti-IUdR antibody and propidium iodide, and fluorescence-activated cell scanning was performed to determine the ratio of IUdR-labeled cells to the total cell population for each IUdR concentration and at each time point. The data were measured three times at each time point. The doubling times, growth curve, and cell density of the proliferating SMCs were investigated by using the Coulter particle counter and digital microscopy. RESULTS The percentage of proliferating SMCs that showed IUdR uptake increased from 1 to 5 days incubation with all concentrations of IUdR; the incorporation rate reached a peak value at day 5 and then decreased by day 7. IUdR uptake on day 5 was higher with concentrations of 10 and 20 micro mol/L. When compared with that of the control group, the doubling times increased with an increase in IUdR concentration, whereas the proliferating cell number and density decreased significantly by days 5 (P < .05) and 7 (P < .01). CONCLUSIONS IUdR uptake peaked on day 5, and the optimal concentration of IUdR for in vitro uptake in proliferating SMCs was 10-20 micro mol/L. IUdR inhibited the proliferation of the SMCs, and the inhibitory effect was related to the concentration.
Collapse
Affiliation(s)
- Yonghua Xu
- Department of Radiology, Indiana University Medical Center, Indianapolis, IN 47405, USA
| | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
The problem of restenosis after percutaneous transluminal coronary angioplasty remains the major limiting factor of the procedure. Over the last 10 years, investigators have been studying the use of radiation therapy for preventing restenosis after angioplasty or stent placement. Since radiotherapy has been proven in other cases to be effective in disrupting the cell cycle regulatory proteins and thereby slowing or stopping growth, it was decided to apply the same principle to neointimal hyperplasia. To review the data that have emerged regarding vascular radiation with an emphasis on irradiated stents, 65 articles were reviewed and both preclinical and clinical experiments were included. Overall, studies with gamma and beta radiation show promising results. Endovascular gamma radiation has been shown effective in randomized trials, even at 3-year follow-up. Beta radiation is preferred because of greater safety and localization, and because it has also shown encouraging results in initial clinical trials, as well as in larger randomized studies. Consequently, the Federal Drug Administration has approved the use of both. In both types of endovascular brachytherapy, it seems the greater the dose, the better the initial response. Safety concerns include an increased incidence of late thrombosis and greater restenosis at margins. With irradiated stents, however, the situation is not as clear. At times, animal models have presented confusing results. These have ranged from significant suppression of hyperplasia to outright adverse effects of radiation on the vessel wall. While some clinical trials have been encouraging, others have not. Follow-up of up to 1 year has been disappointing so far. Many issues, such as the "candy wrapper" effect and rebound hyperplasia, must be dealt with before this becomes a viable form of therapy. It has become clear that radiation therapy in this setting, while having potentially great benefits, can cause deleterious effects as well. However, the mixed bag of positive and negative results seen so far, and the attractiveness of stents or percutaneous transluminal coronary angioplasty being "restenosis-proofed," eventually is cause for cautious optimism.
Collapse
Affiliation(s)
- Nabeel Hafeez
- Department of Internal Medicine, University Hospital, State University of New York at Stony Brook, USA.
| |
Collapse
|
9
|
Dilcher C, Chan R, Justus BL, Falkenstein P, Huston AL, Waksman R. Dose mapping of porcine coronary arteries using an optical fiber dosimeter. CARDIOVASCULAR REVASCULARIZATION MEDICINE 2005; 6:163-9. [PMID: 16326378 DOI: 10.1016/j.carrev.2005.10.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2005] [Accepted: 10/07/2005] [Indexed: 11/15/2022]
Abstract
BACKGROUND This study is about the measurement of radiation dose contribution to the coronary arteries during intravascular brachytherapy with beta and gamma emitters utilizing in vivo optical fiber dosimeters. METHODS AND MATERIALS Domestic pigs were used. With each measurement, catheters were introduced into two different coronary arteries, including the left circumflex (LCX), the left anterior descending (LAD), the first diagonal, and/or the right coronary artery (RCA). A radioactive source (192Ir, 90Sr/Y, or 32P) and the dosimeter were loaded in each of these catheters. Data were collected as the dosimeter was being retracted at a constant rate via computer control. RESULTS The radiation dose was normalized to 100% at a 2-mm radial distance from the source. When radiating a branching artery, the dose to the bifurcation at 5 mm from the source was 35%, 10%, and 3% for the 192Ir (10 seeds), 90Sr/Y (40 mm), and 32P sources, respectively. When utilizing a 23-seed 192Ir source, the dose is 40% at a 5-mm distance. However, radiation of the RCA did not result in dosing to the LAD or LCX using any source. CONCLUSIONS The dose to adjacent artery segments is less with beta than with gamma emitters. Significant dose exposition is noted when using gamma emitters at a distance of 5 mm. The results can serve as a guideline for establishing prescription doses and safety margins for the treatment of bifurcation lesions and retreatment of the arteries.
Collapse
Affiliation(s)
- Christian Dilcher
- Division of Cardiology, Washington Hospital Center, Washington, DC, USA
| | | | | | | | | | | |
Collapse
|
10
|
Fritz P, Stein U, Hasslacher C, Zierhut D, Wannenmacher M, Pritsch M. External beam radiotherapy fails to prevent restenosis after iliac or femoropopliteal percutaneous transluminal angioplasty: results of a prospective randomized double-blind study. Int J Radiat Oncol Biol Phys 2004; 59:815-21. [PMID: 15183485 DOI: 10.1016/j.ijrobp.2003.11.036] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2003] [Revised: 11/17/2003] [Accepted: 11/21/2003] [Indexed: 11/19/2022]
Abstract
PURPOSE Early restenosis is one of the major complications after successful percutaneous transluminal angioplasty (PTA), in main, as well as peripheral, arteries. The effectiveness of hypofractionated external beam radiotherapy (EBRT) as a prophylaxis for restenosis was examined in a prospective, randomized, double-blind, clinical trial. METHODS AND MATERIALS Forty-eight patients underwent sham RT and 47 were treated with daily RT in 3-Gy fractions, to a total dose of 21 Gy. The follow-up lasted for 12 months, and the examinations included pressure measurements and calculations of the ankle-brachial index or duplex sonography ("peak velocity ratio"). If restenosis was suspected, additional angiography was performed. RESULTS No statistically significant difference was found between the treatment groups: sham RT 16 failures (33.3%) and EBRT group 21 failures (45.7%; p = 0.292). EBRT also showed no substantial effects on subgroups classified by the specific length of the lesion or in diabetic patients. CONCLUSION External beam radiotherapy does not prevent restenosis. A reduction in the failure rate >8% using fractionated EBRT with doses aimed at keloid prevention can be ruled out with a probability of 97.5%. Endovascular brachytherapy remains the preferred therapeutic method for achieving restenosis prophylaxis through RT.
Collapse
Affiliation(s)
- Peter Fritz
- Department of Radiotherapy, University of Heidelberg, Heidelberg, Germany.
| | | | | | | | | | | |
Collapse
|
11
|
Zhong GZ, Chen FR, Bu DF, Wang SH, Pang YZ, Tang CS. Cobalt-60 gamma radiation increased the nitric oxide generation in cultured rat vascular smooth muscle cells. Life Sci 2004; 74:3055-63. [PMID: 15081571 DOI: 10.1016/j.lfs.2003.08.049] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2003] [Accepted: 10/08/2003] [Indexed: 11/24/2022]
Abstract
Radiation is a promising and new treatment for restenosis following angioplasty. Nitric oxide has been proposed as a potential "anti-restenotic" molecule. We radiated the cultured rat vascular smooth muscle cells with Cobalt-60 gamma radiation at doses of 14 and 25Gy and observed nitrite production, cGMP content, L-arginine uptake, inducible nitric oxide synthase (iNOS) activity, and the gene expression of iNOS. Results showed that radiation at doses of 14 and 25Gy increased cGMP content by 92.4% and 86.4%, respectively. Radiation at the dose of 25Gy increased the iNOS activity and nitrite content, but radiation at the dose of 14Gy had no significant effect on iNOS activity and NO production. Both doses of radiation significantly decreased the L-arginine transport. Radiation at the doses of 14 and 25Gy increased iNOS gene expression significantly, which was consistent with the effect of radiation on iNOS activity. In conclusion, radiation induces the NO generation by up-regulating the iNOS activity.
Collapse
MESH Headings
- Animals
- Aorta, Thoracic/enzymology
- Aorta, Thoracic/radiation effects
- Arginine/metabolism
- Cells, Cultured
- Cobalt Radioisotopes
- Cyclic GMP/metabolism
- DNA Primers/chemistry
- DNA, Complementary/genetics
- Gamma Rays/adverse effects
- Male
- Muscle, Smooth, Vascular/enzymology
- Muscle, Smooth, Vascular/radiation effects
- Nitric Oxide/biosynthesis
- Nitric Oxide Synthase/genetics
- Nitric Oxide Synthase/metabolism
- Nitric Oxide Synthase Type II
- Nitrites/metabolism
- RNA, Messenger/genetics
- Rats
- Rats, Wistar
- Reverse Transcriptase Polymerase Chain Reaction
- Up-Regulation
Collapse
Affiliation(s)
- Guang Zhen Zhong
- Department of Cardiology, The Third Hospital, Peking University, Beijing 100083, China
| | | | | | | | | | | |
Collapse
|
12
|
Grewe PH, Deneke T, Hanefeld C, Müller KM. Human coronary morphology after beta radiation brachytherapy of in-stent restenosis. BRITISH HEART JOURNAL 2004; 90:e32. [PMID: 15145896 PMCID: PMC1768271 DOI: 10.1136/hrt.2003.026674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
This case report discusses the human coronary morphological findings 18 hours after brachytherapy (beta radiation) of an in-stent restenosis. Brachytherapy produced aseptic inflammation of the periadventitial connective tissue integrating the vasa vasorum in the acute phase. The stent neointima eight months after stenting and acutely 18 hours after radiation consisted of the same cellular components as human stent neointima of specimen not additionally treated with radiation. No evidence of necrosis or excessive fibrotic alterations of the arterial vessel wall have been found.
Collapse
Affiliation(s)
- P H Grewe
- Abteilung fur Kardiologie, Bergmannsleil Bochum, University of Bochum, Germany.
| | | | | | | |
Collapse
|
13
|
Jaster M, Fuster V, Rosenthal P, Pauschinger M, Tran QV, Janssen D, Hinkelbein W, Schwimmbeck P, Schultheiss HP, Rauch U. Catheter based intracoronary brachytherapy leads to increased platelet activation. BRITISH HEART JOURNAL 2004; 90:160-4. [PMID: 14729786 PMCID: PMC1768065 DOI: 10.1136/hrt.2003.013482] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Vascular brachytherapy (VBT) after percutaneous coronary intervention (PCI) is associated with a higher risk of stent thrombosis than conventional treatment. OBJECTIVE To investigate in vivo periprocedural platelet activation with and without VBT, and to assess a possible direct effect of radiation on platelet activation. DESIGN Of 50 patients with stable angina, 23 received VBT after PCI, while 27 had PCI only. The 23 patients who received VBT after PCI were pretreated for one month with aspirin and clopidogrel. Platelet activation was assessed by flow cytometry. RESULTS The two patient groups did not differ in their platelet activation before the intervention. There was a significant increase in activation immediately after VBT, with 21.2% (interquartile range 13.0% to 37.6%) thrombospondin positive and 54.0% (42.3% to 63.6%) CD 63 positive platelets compared with 12.7% (9.8% to 14.9%) thrombospondin positive and 37.9% (33.2% to 45.2%) CD 63 positive platelets before the intervention (p < 0.001 and p < 0.01, respectively). Patients without VBT had no periprocedural difference in platelet activation immediately after PCI. No increase in platelet activation was found after ex vivo irradiation of blood samples obtained from healthy controls. CONCLUSIONS Catheter based intracoronary VBT carried out according to current standards is highly thrombogenic. The current antithrombotic treatment with aspirin and clopidogrel is not sufficient to suppress platelet activation during the procedure. From in vitro experiments, it appears that platelet activation during brachytherapy is not caused by irradiation but by the procedure of catheter based VBT.
Collapse
Affiliation(s)
- M Jaster
- Department of Cardiology, University Hospital Benjamin Franklin, Free University of Berlin, Berlin, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Pręgowski J, Bulski W, Kalińczuk Ł, Kruk M, Witkowski A. Zależność efektu brachyterapii wewnątrznaczyniowej od wielkości dawki. Rep Pract Oncol Radiother 2004. [DOI: 10.1016/s1507-1367(04)71040-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
15
|
Granada JF, Kaluza GL, Raizner AE, Moreno PR. Vulnerable plaque paradigm: Prediction of future clinical events based on a morphological definition. Catheter Cardiovasc Interv 2004; 62:364-74. [PMID: 15224306 DOI: 10.1002/ccd.20059] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Juan F Granada
- Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas, USA.
| | | | | | | |
Collapse
|
16
|
Meyer JMA, Nowak B, Schuermann K, Buecker A, Moltzahn F, Kulisch A, Heussen N, Görgen T, Büll U, Günther RW. Inhibition of Neointimal Proliferation with188Re-labeled Self-Expanding Nitinol Stent in a Sheep Model. Radiology 2003; 229:847-54. [PMID: 14657319 DOI: 10.1148/radiol.2293020368] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE To evaluate a self-expanding rhenium 188 (188Re) radiochemically labeled radioactive stent in sheep. MATERIALS AND METHODS A self-expanding nitinol stent (30 mm in length, 8 mm in diameter) coated with a functionalized polymer layer was radiolabeled with 188Re. Fifty prostheses, 25 of which were radioactive (mean radioactivity, 20 MBq +/- 3.8 [SD]) and 25 of which were nonradioactive, were implanted into the external iliac arteries of 25 sheep. Stent patency was assessed with angiography. Neointimal formation was assessed with intravascular ultrasonography and histologic examination 1 month (in all sheep) and 3 months (in 12 sheep) after implantation. The results were analyzed by using repeated-measures analysis of variance with two repeated factors and paired t tests for comparison at each measuring point. RESULTS All stents were placed successfully. Data in one animal had to be excluded from the study. After 3 months, a mean neointimal area reduction of 70 mm2 +/- 55 (SD) was observed inside the radioactive stents, and a mean lumen reduction of 126 mm2 +/- 39 was observed inside the nonradioactive control stents (P =.022). An edge effect was observed in the radioactive stents in that they showed an amount of neointimal formation at the edges that was similar to that seen in control stents. This neointimal formation accounted for the maximum lumen loss in the vascular segment with the stent. CONCLUSION As compared with a nonradioactive stent, a beta particle-emitting stent, through endovascular irradiation, significantly inhibits neointimal formation inside the stent but not at the stent edges.
Collapse
Affiliation(s)
- Julius M A Meyer
- Department of Diagnostic Radiology, University of Technology, Pauwelsstrasse 30, Aachen D-52074, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Brenner B, Kramer MR, Katz A, Feinmesser R, Weissmann-Brenner A, Sulkes A, Fenig E, Brenner-Weissman A. High Dose Rate Brachytherapy for Nonmalignant Airway Obstruction. Chest 2003; 124:1605-10. [PMID: 14555598 DOI: 10.1378/chest.124.4.1605] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
STUDY OBJECTIVES High dose rate (HDR) endobronchial brachytherapy is widely used as a palliative treatment for symptomatic airway obstruction by primary or secondary malignant tumors. We report on a successful use of HDR brachytherapy in patients with nonmalignant airway obstruction. DESIGN Case series PATIENTS Six patients received HDR brachytherapy for airway obstruction caused by granulation tissue around a metal stent placed for restoration of the airway patency for nonmalignant causes. In four patients, brachytherapy was performed following recurrent occlusion of the airway by granulation tissue formation; in two patients, it was done as a prophylactic procedure. INTERVENTION HDR brachytherapy catheters were passed through the metal stents under direct fluoroscopic guidance. Simulation and computerized treatment planning were done, and a single dose of 10 Gy was administered using a brachytherapy remote afterloader with a (192)Ir source. The dose was prescribed to a distance of 1 cm from the center of the source, with a margin of 1 cm from the proximal and distal ends of the stent. RESULTS At a median follow-up of 15 months, moderate granulation tissue formation was observed in only one patient; in four others, it was categorized as minimal, 5 to 30 months from the procedure. Restoration of the lumen was complete in four patients, near complete in one patient, and partial in one patient. In one patient, previously treated by external radiotherapy, local tissue necrosis was evident. CONCLUSION HDR brachytherapy can be used safely for nonmalignant airway obstruction. Further studies including more patients and longer follow-up are needed.
Collapse
Affiliation(s)
- Baruch Brenner
- Oncology Institute, Rabin Medical Center, Beilinson Campus, and Sackler Faculty of Medicine, Tel Aviv University, Petah Tiqva, Israel
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Maeng M, Busk M, Tanderup K, Mertz H, Andersen HR, Thuesen L. Catheter-based 32P beta-radiation after stent implantation in porcine coronary arteries: role of source-centering and geographical miss. Catheter Cardiovasc Interv 2003; 60:247-57. [PMID: 14517934 DOI: 10.1002/ccd.10608] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The present study examined the role of source-centering and geographical miss in vascular brachytherapy. After implantation of 13 mm long stents, 38 coronary arteries in 13 pigs were randomly assigned to centered brachytherapy (n = 13), eccentric brachytherapy (n = 13), or no radiation (n = 12). Geographical miss was avoided by careful placement of a 27 mm (32)P beta-radiation source. Restenosis was quantified by angiography, histomorphometry, and intravascular ultrasound at 28 days. Source-centering led to a significant (P < 0.001) reduction of in-stent area stenosis (centered radiation, 12% +/- 5%; eccentric radiation, 37% +/- 21%; control arteries, 41% +/- 13%). Despite 7 mm coverage of the edge segments, radiation was found to induce edge stenosis due to neointima formation and constrictive vascular remodeling. We conclude that centered radiation was superior to eccentric radiation in reducing in-stent luminal narrowing while radiation-induced edge stenosis was still observed despite extension of the radiation zone to 7 mm beyond the stent edges.
Collapse
Affiliation(s)
- Michael Maeng
- Department of Cardiology, Aarhus (Skejby) University Hospital, Aarhus, Denmark.
| | | | | | | | | | | |
Collapse
|
19
|
Jeong JM, Chung JK. Therapy with 188Re-Labeled Radiopharmaceuticals: An Overview of Promising Results from Initial Clinical Trials. Cancer Biother Radiopharm 2003; 18:707-17. [PMID: 14629819 DOI: 10.1089/108497803770418256] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The development of an in-house 188W/188Re-generator has greatly increased the use of 188Re for treating various diseases. 188Re is of widespread interest due to its attractive physical and chemical properties. Many new radiopharmaceuticals labeled with 188Re have been developed and are currently in clinical trials, such as: 188Re-labeled renal excreting agents like 188Re-mercaptoacetylglycylglycylglycine (MAG3) and 188Re-diethylenetriamine pentaacetic acid (DTPA) for prevention of coronary arterial restenosis; 188Re-labeled phosphonates such as 188Re-hydroxyethylidene diphosphonate (HEDP), 188Re-alendronate (ABP), and 188Re-ethylenediamine-N,N,N',N'-tetrakis(methylene phosphoric) acid (EDTMP) for palliation of metastatic bone pain; 188Re-labeled lipiodol such as 188Re-n-hexyldiaminedithiol (HDD)-lipiodol for treatment of liver cancer; and 188Re-labeled colloids and microspheres for treatment of diseases such as rheumatoid arthritis, peritoneal effusion, and other solid tumors. However, there is still a need to develop new 188Re-labeled radiopharmaceuticals that are more specific for target lesions such as cancer-specific monoclonal antibodies and peptides. The availability of 188Re from a generator at a reasonable cost may help increase not only the research activities but also the clinical applications of 188Re-labeled radiopharmaceuticals.
Collapse
Affiliation(s)
- Jae Min Jeong
- Department of Nuclear Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | | |
Collapse
|
20
|
Qu X, Weinberger J. Deposition of (90)YPO(4) and (144)CePO(4) radioisotopes on polymer surfaces for radiation delivery devices. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH 2003; 63:98-105. [PMID: 11870641 DOI: 10.1002/jbm.10095] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Intravascular irradiation with beta emitters inhibits restenosis in arteries after balloon angioplasty or stent implantation. Yttrium-90 ((90)Y, T(1/2)=64 h) and cerium-144 ((144)Ce, T(1/2)=286 d) emit beta particles (E(max)=2.28--3.50 MeV) having an ideal energy range for brachytherapy delivery system. In this article, a previously reported method for depositing (32)P on poly(ethylene terephtalate) (PET) surfaces is generalized and modifications that allow deposition of other beta-emitting radioisotopes, such as (90)Y and (144)Ce, are demonstrated. PET films were first coated with chitosan hydrogel and then adsorbed different amounts of phosphoric acid (PA) in aqueous solutions. Yttrium was deposited onto the surface as YPO(4) after the films were immersed in YCl(3) solutions. 1 muCi (90)YCl(3) (2 x 10(-9) g) was used in each sample as a tracer for measuring the deposition efficiency, which is defined as the percentage of YCl(3) deposited on the surface compared to the amount of YCl(3) in solutions before the deposition. In order to improve the safety of brachytherapy treatments, polyurethanes were used to seal the deposited radioisotopes on the surface to minimize the leakage of the isotopes into the patients. The generality of this method presented here for a wide variety of particular radioisotopic components allows design of a broad range of versatile radioisotope sources.
Collapse
Affiliation(s)
- Xin Qu
- Interventional Cardiology Center, Department of Medicine, Columbia University, 161 Fort Washington Avenue, AP-551, New York, New York 10032, USA.
| | | |
Collapse
|
21
|
Abstract
Restenosis is a major limitation of coronary angioplasty, requiring further intervention in the majority of cases. Intracoronary radiation has been employed in recent years to prevent restenosis lesions with effective results, principally in in-stent restenosis. Restenosis is generally considered as an excessive form of normal wound healing divided up in processes: elastic recoil, neointimal hyperplasia, and negative vascular remodeling. Restenosis has previously been regarded as a proliferative process in which neointimal thickening, mediated by a cascade of inflammatory mediators and other factors, is the key factor. Data from recent studies have pointed to negative vascular remodeling as a major contributing factor. Recent studies have also identified particular cell lines that might be critical regulators of restenosis, particularly monocyte-derived macrophages and myofibroblasts. This review summarizes the current theories of vascular biology pertaining to restenosis in coronary arteries and the potential mechanisms of why radiation may effectively inhibit restenosis.
Collapse
Affiliation(s)
- Smith Apisarnthanarax
- Department of Radiation Oncology, Rhode Island Hospital, Brown Medical School, Providence, Rhode Island 02903, USA
| | | |
Collapse
|
22
|
Rodriguez VM, Grove J, Yelich S, Pearson D, Stein M, Pevec WC. Effects of brachytherapy on intimal hyperplasia in arteriovenous fistulas in a porcine model. J Vasc Interv Radiol 2002; 13:1239-46. [PMID: 12471188 DOI: 10.1016/s1051-0443(07)61971-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
PURPOSE The hypotheses of this investigation were that endovascular radiation would reduce intimal hyperplasia in arteriovenous fistulas (AVFs) and that this reduction would be associated with decreased expression of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-A, and tumor necrosis factor (TNF)-alpha. MATERIALS AND METHODS Bilateral end jugular vein-to-side carotid artery fistulas were constructed in pigs. At 48 hours, one AVF was randomly selected for endovascular radiation with (192) Iridium. The contralateral fistula received no radiation and served as a control. Animals in group 1 (n = 7) received 14 Gy of radiation at a depth of 2 mm and tissue was harvested at 29 days; animals in group 2 received 7 Gy of radiation at a depth of 2 mm and tissue was harvested at 29 days (n = 8); and animals in group 3 received 7 Gy of radiation at a depth of 2 mm and tissue was harvested at 56 days (n = 8). The area and maximum thickness of intimal hyperplasia were then measured blindly. Immunohistochemical results for VEGF, PDGF-A, and TNFalpha were obtained and analyzed blindly by assigning a score of 0-3, with 0 indicating no staining and 3 indicating maximum staining. RESULTS Irradiation with 14 Gy caused severe fibrosis in the media of the vein, with thrombosis of three of seven AVFs. Compared with the control group, the group that underwent irradiation with 7 Gy had significantly reduced intimal area at 56 days (9.9 mm(2) +/- 4.9 vs 2.1 mm(2) +/- 1.1; P =.001). This reduction correlated with significant reduction in the expression of VEGF (score of 2.2 +/- 0.1 vs 1.2 +/- 0.2; P =.001) and TNFalpha (1.3 +/- 0.1 vs 0.9 +/- 0.1; P =.04). CONCLUSION Fourteen grays is an excessive radiation dose for veins, causing medial fibrosis and thrombosis of the AVF. Irradiation with 7 Gy effectively inhibited the formation of intimal hyperplasia in AVF. This inhibition correlated with decreased expression of VEGF and TNFalpha.
Collapse
Affiliation(s)
- Victor M Rodriguez
- Department of Surgery, University of California Davis Medical Center, Sacramento, CA 95817, USA
| | | | | | | | | | | |
Collapse
|
23
|
Derntl M, Syeda B, Beran G, Schukro C, Denk S, Glogar D. Prevention of stent thrombosis following brachytherapy and implantation of drug-eluting stents. J Interv Cardiol 2002; 15:477-83. [PMID: 12476651 DOI: 10.1111/j.1540-8183.2002.tb01092.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The implementation of coronary brachytherapy and especially the application of drug-eluting stents for the prevention of in-stent restenosis are of vital importance in the field of interventional cardiology. Despite undeniable benefits of these new methods a potential increased risk for the occurrence of stent thrombosis as a result of the mode of action of these new methods has to be taken into consideration. The prevention of stent thrombosis following coronary brachytherapy and implantation of drug-eluting stents is therefore of particular importance to assure the success of these forward-looking technologies. This article provides an overview of current data regarding the incidence of stent thrombosis following brachytherapy and implantation of drug-eluting stents and it's implication for clinical practice.
Collapse
Affiliation(s)
- Michael Derntl
- Department of Internal Medicine II/Division of Cardiology, University of Vienna, Vienna, Austria
| | | | | | | | | | | |
Collapse
|
24
|
Miften MM, Das SK, Shafman TD, Marks LB. Optimization of a 90Sr/90Y radiation source train stepping for intravascular brachytherapy. Med Phys 2002; 29:2891-6. [PMID: 12512724 DOI: 10.1118/1.1524169] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
A steepest-descent gradient algorithm is developed to optimize the stepping of a 90Sr/90Y radiation source train (RST) for intravascular brachytherapy (IVB). The objective function is to deliver a uniform dose in a coronary target vessel and minimize the dose in adjacent normal vessel tissue at the proximal and distal edges of the coronary target vessel. Based on the target length and number of dwell points (number of steps), the algorithm modulates the dwell times and corresponding dwell positions that optimize the weighted addition of staggered EGS4 Monte Carlo (MC) calculated dose distribution from a single RST. Stepping treatment plans are generated for target vessel lengths of 3.0, 3.3, and 3.8 cm. For both the unoptimized and optimized plans, the dose heterogeneity in the target vessel wall, and length of nontarget vessel receiving 3 Gy, is assessed to compare plans. Optimization results show a 14% dose uniformity within the target is achievable for all vessel lengths. Further, the dose in the adjacent normal tissue is lower in the optimized plans than the unoptimized plans. The work presented in this paper provides a model to address the finite length of RST in IVB treatments. While the results presented are specific to the 90Sr/90Y RST, the methods should apply to other finite length RSTs.
Collapse
Affiliation(s)
- Moyed M Miften
- Department of Radiation Oncology, Duke University Medical Cente, Durham, North Carolina 27710, USA.
| | | | | | | |
Collapse
|
25
|
Morino Y, Kaneda H, Fox T, Takagi A, Hassan AHM, Bonan R, Crocker I, Lansky AJ, Laskey WK, Suntharalingam M, Bonneau HN, Yock PG, Honda Y, Fitzgerald PJ. Delivered dose and vascular response after beta-radiation for in-stent restenosis: retrospective dosimetry and volumetric intravascular ultrasound analysis. Circulation 2002; 106:2334-9. [PMID: 12403663 DOI: 10.1161/01.cir.0000036367.17043.03] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Observations from previous intracoronary radiation therapy trials noted a considerable discrepancy between the prescribed radiation dose and the dose actually delivered. The aims of this study were to investigate the effect of actual delivered dose on vascular changes and to test the appropriateness of the current dose prescription. METHODS AND RESULTS Serial volumetric intravascular ultrasound (IVUS) analysis was performed in 30 in-stent restenosis cases treated with a 40-mm (90)Sr/Y source train. The fixed dose was prescribed at 2 mm from the centerline of the source train (18.4 Gy at 2 mm for reference diameter < or =3.35 mm and 23 Gy for diameter > or =3.36 mm). Only stent segments with full radiation coverage and device injury were enrolled and divided into 2-mm-long subsegments (n=202). D(S90)EEM (the minimum dose absorbed by 90% of the external elastic membrane surface) was calculated as the delivered dose corresponding to each segment, assuming that the radiation catheter occupied the same position in the vessel as the IVUS catheter. Mean D(S90)EEM of 23.5+/-5.82 Gy (range 12.3 to 41.7 Gy) was delivered to these subsegments. Overall, intimal hyperplasia volume remained constant from postintervention to follow-up (2.23+/-1.10 to 2.32+/-1.09 mm3/m; P=NS). Regression analysis revealed there was no correlation between delivered dose intensity and changes in intimal hyperplasia volume. No particular dose-dependent complications were appreciated in this delivered dose range. CONCLUSIONS The current dose-prescription protocol of (90)Sr/Y radiation to native in-stent restenosis lesions may provide substantial inhibition of neointimal reproliferation regardless of the actual delivered dose intensity.
Collapse
Affiliation(s)
- Yoshihiro Morino
- Center for Research in Cardiovascular Interventions, Stanford University Medical Center, Stanford, Calif 94305-5637, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Le Blanche AF, Bonneau M, Wassef M, Farrès MT, Gabez L, Aubert B, Duriez M, Lévy BI, Bigot JM, Boudghene F. Histomorphometric evaluation of (198)Au endovascular brachytherapy in a renal artery restenosis model in rabbits. AJR Am J Roentgenol 2002; 179:611-8. [PMID: 12185028 DOI: 10.2214/ajr.179.3.1790611] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE The main mid-term complication of percutaneous transluminal angioplasty of the renal artery is restenosis, which occurs in up to 50% of patients. Although no pharmacologic agent to date has been effective in preventing restenosis, both beta-ray emitters and gamma-ray emitters used in endovascular brachytherapy have been shown to reduce coronary restenosis. The objectives of this study were to evaluate the efficacy of (198)Au endovascular brachytherapy in preventing restenosis after percutaneous transluminal renal angioplasty and to determine the radiation dose to the operator. MATERIALS AND METHODS Twenty-one New Zealand white rabbits (10 females and 11 males) weighing an average of 3.5 kg (range, 3.2-3.8 kg) who had been fed a normal diet underwent bilateral 33% overdilatation with deendothelialization of the renal arteries. After 7 weeks, the induced renal artery stenoses were treated by percutaneous transluminal renal angioplasty. The rabbits were randomly assigned to one of three groups before receiving endovascular 25-Gy irradiation at a radial 2.0-mm depth with a 0.5 x 15 mm (198)Au wire (106 MBq). The right renal artery was irradiated in group A; the left, in group B. The rabbits in group C randomly received a right- or left-sided dummy wire. Operator exposure to radiation was measured using thermoluminescent dosimeters and ionization chambers. The rabbits were sacrificed after 3 weeks. The aorta and renal arteries were perfusion-fixed. The renal arteries were removed for histologic and histomorphometric study. RESULTS Forty-two renal arteries were cut into a series of 4- micro m-thick slices. Five arteries were thrombosed (two in the irradiated group and three in the control group, p > 0.05). In the patent arteries (n = 37), the average neointimal area was 0.068 mm(2) (range, 0.009-0.234 mm(2)) in 15 irradiated segments (315 slices total), whereas the average neointimal area was 0.135 mm(2) (range, 0.016-0.324 mm(2)) in 22 control segments (462 slices total) (analysis of variance, p < 0.009), showing a percentage area of restenosis of 10.4% in irradiated arteries and 43.4% in non-irradiated arteries (p < 0.0003). Radiation dose per procedure to the operator was 0.034 mSv in the index finger, 0.024 mSv in the wrist, and undectable in the body. CONCLUSION Endovascular brachytherapy with (198)Au appears to inhibit early renal artery restenosis and exposes the operator to a safe level of radiation.
Collapse
Affiliation(s)
- Alain F Le Blanche
- Department of Radiology, Hôpital Universitaire Tenon, AP-HP, 4, rue de la Chine, F-75970 Paris Cedex 20, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
Coronary artery disease is the leading cause of mortality in the West with over 1.2 million angioplasties performed annually. Despite the introduction of stents, restenosis occurs in 30-40% of vessels, which until recently has only been treated effectively by coronary artery bypass surgery. Coronary artery brachytherapy appears to provide an alternative, less invasive remedy. The mechanisms of restenosis and how these are inhibited by radiation are described here. The practicalities of radiation delivery and the history of the development of intravascular radiation as an effective clinical tool are outlined. Finally, the pitfalls of the current technology and the areas in which future research must be targeted for the field to develop are discussed.
Collapse
Affiliation(s)
- E C Sims
- Department of Cardiac, Vascular and Inflammation Research, Bart's and The London, Queen Mary's School of Medicine and Dentistry, UK
| | | | | | | |
Collapse
|
28
|
Kepka C, Pszona S, Bulski W, Witkowski A. The "shielding" effect of the guide wire during coronary brachytherapy with P-32 source. CARDIOVASCULAR RADIATION MEDICINE 2002; 3:205-8. [PMID: 12974375 DOI: 10.1016/s1522-1865(03)00099-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Intracoronary beta irradiation (use of beta radiation for intracoronary irradiation) is an effective method in reducing neointimal proliferation after successful angioplasty and stent implantation. However, long-term results may be influenced by absolute dose and by the homogeneity in dose distribution. In our study, we investigated dose perturbation due to the presence of a conventional guide wire during irradiation. The Galileo III centering catheter and P-32 beta source were used. The 55 MD GAF Chromic foil was positioned within a phantom made of PMMA. The dose distribution at cylindrical surfaces has been assessed using GAF Chromic dosimetric foil MD55 (Nuclear Associates, USA). Our study demonstrated the significant dose reduction of 46% in the most "shaded" area. The dose reduction to 80% or less occupy the 60 degrees sector. This phenomenon can cause progression of late restenosis. In conclusion, the results suggest that technical improvements in centering catheter construction should be made to eliminate the "shielding" effect of the guide wire.
Collapse
Affiliation(s)
- Cezary Kepka
- Haemodynamical Department, Institute of Cardiology, Alpejska 42, 04-628 Warsaw, Poland.
| | | | | | | |
Collapse
|
29
|
Maehara A, Patel NS, Harrison LB, Weissman NJ, Bui AB, Kim HS, Ajani AE, Castagna MT, McMillan TL, Yang N, Chan R, Pisch J, Quan H, Chiu-Tsao ST, Waksman R, Mintz GS. Dose heterogeneity may not affect the neointimal proliferation after gamma radiation for in-stent restenosis: a volumetric intravascular ultrasound dosimetric study. J Am Coll Cardiol 2002; 39:1937-42. [PMID: 12084591 DOI: 10.1016/s0735-1097(02)01880-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
OBJECTIVES The goal of this study was to use serial (postirradiation and follow-up) volumetric intravascular ultrasound (IVUS): 1) to evaluate the actual distribution of gamma radiation in human in-stent restenosis (ISR) lesions, and 2) to analyze the relationship between neointimal regrowth and the delivered radiation dose. BACKGROUND The relationship between the neointimal regrowth and delivered dose during the treatment of ISR remains unknown. METHODS We analyzed 20 actively (gamma emitter) treated, native artery ISR patients from the Washington Radiation for In-Stent restenosis Trial (WRIST) that met the following criteria: on both postirradiation and six-month follow-up IVUS imaging, > or =80% of the external elastic membrane circumference could be identified throughout the treated length including the lesion and proximal and distal reference segments. Intravascular ultrasound images were digitized every 1 mm. Proximal and distal reference and stented segment luminal and adventitial contours were imported and reconstructed. The source was placed circumferentially at the site of the IVUS catheter and longitudinally according to the relationship between the radioactive seeds and stent edges. Using Monte Carlo simulations, dose volume histograms for the adventitia and intima were calculated. The relationship between the neointimal regrowth and calculated doses were evaluated. RESULTS There was large dose heterogeneity at both the intimal and adventitial levels. Most of the sites (93%) received >4 Gy at the adventitia, and all of the sites received >4 Gy at the intima. There was no relationship between neointimal regrowth and radiation dose. CONCLUSIONS Although there may be large dose heterogeneity, gamma irradiation (using a fixed dose prescription) appears to deliver a sufficient dose to prevent neointimal regrowth.
Collapse
Affiliation(s)
- Akiko Maehara
- Cardiovascular Research Institute, Washington Hospital Center, Washington DC 20010, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
Within the past decade, focus on radiation to prevent restenosis has moved from a concept developed in the animal laboratory to a clinical treatment. The initial evaluation of coronary artery radiation therapy focused on changes in the function of the artery or lesion formation following overstretch balloon injury in pigs. A number of concepts emerged from this work: (1) radiation inhibits neointima formation in a dose-dependent fashion, (2) radiation prevents negative remodeling, (3) radiation does not reverse established injury, (4) low dose irradiation in an injured area may be injurious, (5) radiation is a useful adjunct to stenting, (6) benefits of radiation in animal models at 6 months are less pronounced than at 1 month, (7) radiation delays healing, (8) permanent stents and radiation delivered from external sources may have very different effects on restenosis, and (9) radiation interferes with vessel wall function. More recent studies of irradiation have looked at the molecular biological effects of radiation in hopes of understanding how this therapy works, and how it may be improved. This article attempts to summarize the known animal and cellular work on radiation in preventing restenosis.
Collapse
Affiliation(s)
- Ian Crocker
- Emory University School of Medicine, and Atlanta Cardiovascular Research Institute, Atlanta, GA, USA.
| | | |
Collapse
|
31
|
Kałuza GL, Jenkins TP, Mourtada FA, Ali NM, Lee DP, Okura H, Fitzgerald PJ, Raizner AE. Targeting the adventitia with intracoronary beta-radiation: comparison of two dose prescriptions and the role of centering coronary arteries. Int J Radiat Oncol Biol Phys 2002; 52:184-91. [PMID: 11777637 DOI: 10.1016/s0360-3016(01)01806-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
PURPOSE To compare by intravascular ultrasound (IVUS) the efficacy of delivering the prescribed dose to the adventitia between two commonly used dose prescriptions for intracoronary radiotherapy. METHODS AND MATERIALS In 59 human postangioplasty coronary vessels, one IVUS cross-section (1 mm thick) with the highest plaque burden was used for creating dose-volume histograms with different hypothetical positions of the source. RESULTS On average, prescription to 1 mm beyond lumen surface resulted in delivery of the prescribed dose (20 Gy +/- 20%) to a higher fraction of adventitial volume than with the prescription to 2 mm from the source, with source placed in vessel center, lumen center, or in the IVUS catheter position. Source placement in the lumen center resulted in a low dose heterogeneity to the adventitia and the least dose heterogeneity to the intima. CONCLUSIONS Prescription to 1 mm beyond lumen surface appeared more effective in delivering the prescribed dose to the adventitia than the American Association of Physicists in Medicine (AAPM) recommended prescription to 2 mm from the source center. Moreover, centering the source in the lumen provides the better balance of effective adventitial targeting and intimal dose homogeneity. Modification of the current AAPM recommendation for dose prescription for intracoronary radiotherapy should be considered.
Collapse
Affiliation(s)
- Grzegorz L Kałuza
- Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Garas SM, Huber P, Scott NA. Overview of therapies for prevention of restenosis after coronary interventions. Pharmacol Ther 2001; 92:165-78. [PMID: 11916536 DOI: 10.1016/s0163-7258(01)00168-1] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Coronary artery disease is a leading cause of morbidity and mortality in the United States and across the world. The economic impact of coronary artery disease is staggering and on the rise. Percutaneous transluminal coronary angioplasty is widely used to treat severe, symptomatic coronary stenosis. The Achilles heel of angioplasty is restenosis of those treated arteries. As a result, numerous therapies, including mechanical and pharmacological approaches, to prevent restenosis have been studied. A greater understanding of the pathophysiology of restenosis has enhanced the success of these therapeutic approaches. To date, the most important and successful approach to limit restenosis has been the use of coronary stents. Stents have reduced the rate of restenosis from approximately 50% down to 20-30%. However, in-stent restenosis presents a new and an even more challenging dilemma. The success of adjunctive drug therapy has been promising, but, as of yet, very limited. Antithrombotic agents have reduced acute thrombosis and many of the acute complications of angioplasty. New approaches and therapies are very encouraging, and provide great hope in the treatment of restenosis. Brachytherapy has shown success in the treatment of in-stent restenosis, and recently has been approved by the United States Food and Drug Administration for this indication. Drug-eluting stents using antiproliferative drugs are the most exciting new advance in preventing restenosis, currently in Phase III trials. Gene therapy, targeted drug delivery, and newer antithrombotic agents are also under investigation. We will review the pathophysiology of restenosis, animal models, pharmacological therapies, and mechanical approaches for the treatment of restenosis.
Collapse
Affiliation(s)
- S M Garas
- Division of Cardiology, Emory University, Atlanta, GA 30322, USA
| | | | | |
Collapse
|
33
|
Abstract
Intracoronary radiation therapy or intracoronary brachytherapy has been developed as an attempt to decrease restenosis after percutaneous coronary interventions. Two parallel technologies, one employing radioactive stents, the other catheter-based radiation (using either beta- or gamma- emitters), have been the subject of numerous animal and human studies. In vivo intravascular ultrasound imaging studies have played a major role in determining the possible mechanism of action of intracoronary radiation therapy and the pathogeny of many of the complications related to the use of this technique. This manuscript is aimed at revising the potential and limitations of intracoronary brachytherapy, as well as at summarizing the results of the currently reported clinical trials.
Collapse
Affiliation(s)
- M Sabaté
- Servicio de Cardiología Intervencionista. Hospital Clínico Universitario San Carlos. Madrid, Spain.
| |
Collapse
|
34
|
Kałuza GL, Raizner AE, Mazur W, Schulz DG, Zymek PT, Nguyen-Ho P, Tio FO, Fajardo LF, Ali NM. Dose-response study of intracoronary beta-radiation with 32P in balloon- and stent-injured coronary arteries in swine. CARDIOVASCULAR RADIATION MEDICINE 2001; 2:225-30. [PMID: 12160764 DOI: 10.1016/s1522-1865(01)00089-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
PURPOSE A dose-response study was performed in swine to investigate the vascular effects of 32P over a broad range of doses in order to define the therapeutic window of intracoronary radiotherapy (ICR) with 32P. METHODS AND MATERIALS A total of 131 porcine arteries were subjected to balloon injury or stenting followed by 0-36 Gy of ICR from a centered 32P source wire to 1 mm beyond lumen surface or a sham ICR procedure. Animals were euthanized at 4 weeks, and vessels were harvested for histomorphometry. RESULTS In the balloon-injured arteries, doses of 7 and 9 Gy did not impact restenosis. At doses of 14-36 Gy, neointima was markedly reduced, with mild dilatation at the highest dose, 36 Gy. In the stent-injured arteries, the lowest dose of 9 Gy failed to reduce neointimal growth, while 14-26 Gy showed the most favorable response. CONCLUSIONS ICR with 32P features a broad therapeutic window. Doses of 14-26 Gy to 1 mm beyond lumen surface provided an optimal combination of efficacy and safety. Doses of 7 and 9 Gy were generally ineffective, suggesting a minimum threshold for ICR with 32P to effectively inhibit restenosis.
Collapse
Affiliation(s)
- G L Kałuza
- Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Nowak B, Meyer JM, Goergen T, Fluehs D, Block S, Guenther RW, Hoecker H, Buell U. Dosimetry of a 188rhenium-labeled self-expanding stent for endovascular brachytherapy in peripheral arteries. CARDIOVASCULAR RADIATION MEDICINE 2001; 2:246-53. [PMID: 12160767 DOI: 10.1016/s1522-1865(02)00131-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Radioactive stents have been proposed as endovascular irradiation device to prevent in-stent restenosis by inhibiting neointimal proliferation. 32P-stents have been used in several studies so far, but require large-scale labeling procedures and endovascular barotrauma for stent expansion supporting the development of edge restenosis. Purpose of this study was to establish dosimetry of a self-expanding nitinol stent for peripheral vascular disease, which was radiolabeled with 188rhenium (188Re) by a dip coating technique. METHODS AND MATERIALS The surface of nitinol Memotherm FLEXX stents was polymer-coated providing functional NH(2) groups for diethylenetriaminepentaacetic acid (DTPA) binding, providing the ligand for the complexation of 188Re onto the stent surface. Stability of radiolabeling was tested over 48 h using an in vitro blood circulation (Chandler Loop). Radial and longitudinal dose distributions of a radiolabeled stent were obtained with a plastic scintillator dosimetry system. RESULTS Stents with a length of 30 mm and a diameter of 8 mm were labeled with up to 33 MBq 188Re. A total of 69+/-4% of the labeled 188Re remained stable on the stent surface after 48 h. Ninety-five percent of the infinitely accumulated dose was supplied to the target tissue within 72 h. Including correction for radioactivity washout from the stent, the infinitely accumulated dose at 1 mm radial distance from the stent surface was 1.85+/-0.19 Gy/MBq 188Re/cm stent length. CONCLUSIONS We developed a technique for radiolabeling of self-expanding nitinol stents with 188Re by dip coating and formation of 188Re chelate complexes. We provide dosimetry data useful for application of this beta-emitting stent for endovascular brachytherapy in peripheral vascular occlusive disease.
Collapse
Affiliation(s)
- B Nowak
- Department of Nuclear Medicine, Aachen University of Technology, Pauwelsstrasse 30, 52074 Aachen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Waksman R, Laird JR, Jurkovitz CT, Lansky AJ, Gerrits F, Kosinski AS, Murrah N, Weintraub WS. Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. J Vasc Interv Radiol 2001; 12:915-21. [PMID: 11487671 DOI: 10.1016/s1051-0443(07)61569-3] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
PURPOSE To conduct a feasibility study to assess the feasibility, safety, and outcome of endoluminal gamma radiation therapy after balloon angioplasty of superficial femoral artery (SFA) lesions. MATERIALS AND METHODS Forty patients with claudication were enrolled in the study and underwent percutaneous transluminal angioplasty (PTA) of SFA lesions with a mean lesion length of 9.8 cm +/- 3.0 and a mean reference vessel diameter of 5.2 mm +/- 3.1. After successful PTA, a segmented centering balloon catheter was positioned to cover the PTA site. The patients were then transported to the radiation oncology suite and treated with a microSelectron HDR afterloader with use of an Ir-192 source with a prescribed dose of 14 Gy, 2 mm into the vessel wall. Ankle-brachial index (ABI) and Rutherford score were evaluated at 1, 6, and 12 months after the procedure and angiographic follow-up was conducted at 6 months. RESULTS Radiation was delivered successfully to 35 of 40 patients. There were no procedural complications. Exercise and rest ABI were higher at 1 year (0.72 +/- 0.26 and 0.89 +/- 0.18, respectively) compared to baseline (0.51 +/- 0.25 and 0.67 +/- 0.17, respectively). Maximum walking time on a treadmill increased from 3.41 min +/- 2.41 to 4.43 min +/- 2.49 at 30 days and was 4.04 min +/- 2.8 at 12 months. The angiographic binary restenosis rate at 6 months was 17.2% and the clinical restenosis rate at 12 months was 13.3%. There were no angiographic or clinical adverse events related to the radiation therapy. CONCLUSIONS Intraarterial radiation after PTA of SFA lesions with use of high-dose rate gamma radiation is feasible and safe. The angiographic and clinical improvements are sustainable at 1 year and represent a potent antirestenotic therapy for the treatment of narrowed peripheral arteries.
Collapse
Affiliation(s)
- R Waksman
- Cardiovascular Research Institute, Washington Hospital Center, 110 Irving St. NW, Washington, DC 20010, USA.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Kollum M, Cottin Y, Chan RC, Kim HS, Bhargava B, Vodovotz Y, Waksman R. Decreased adventitial neovascularization after intracoronary irradiation in swine: a time course study. Int J Radiat Oncol Biol Phys 2001; 50:1033-9. [PMID: 11429231 DOI: 10.1016/s0360-3016(01)01570-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
BACKGROUND Intracoronary radiation (IR) suppresses the formation of neointima after arterial injury in swine, through mechanisms incompletely understood. Neointimal development appears related to expansion of adventitial microvessels; we therefore examined the hypothesis that IR inhibits neointima formation through an anti-angiogenic effect. METHODS AND RESULTS Juvenile swine were treated with either 0 or 15 Gy (192)Ir (gamma-source) and euthanized 3, 7, or 14 days later or treated with 18 Gy (90)Y (beta-source) and euthanized after 14 days. Adventitial area (AA), intimal area (IA), IA corrected for medial fracture length, and adventitial vessel area were assessed in both injured and uninjured segments by computer-aided histomorphometry on Verhoeff-Von Giesson stained sections. Adventitial vessel count (AVC) was enumerated visually on hematoxylin and eosin stained sections and confirmed by anti-factor VIII-associated antigen immunostaining for endothelial cells. AA and IA were reduced in injured arteries subjected to IR as compared to controls. The AVC was significantly lower in injured irradiated arterial segments as well as all uninjured segments as compared with injured control segments. In the injured and irradiated arteries, the AVC remained unchanged at 3, 7, and 14 days. The injured segments of arteries treated with IR demonstrated a significantly lower adventitial microvessel density (AVC/AA) as compared to the injured control segments. Comparison of gamma- and beta-irradiation at 14 days did not show any differences for vessel parameters and measurements of adventitial microvessels. IA and AVC were correlated positively (R(2) = 0.63, alpha = 0.79, p < 0.01). CONCLUSION IR induced an early and sustained anti-angiogenic effect between 3 and 14 days. The relation between IA and AVC may indicate an antiproliferative effect associated with an anti-angiogenic effect independent of the type of radiation. CONDENSED ABSTRACT Intracoronary radiation suppresses neointima formation after arterial injury in swine, through mechanisms and with consequences that are not fully known. Reduction of angiogenesis may inhibit restenosis. In the present study, intimal area and adventitial area were reduced in the intracoronary radiation groups 3-14 days after arterial injury as compared to their respective controls, with a parallel reduction in the adventitial vessel count and adventitial vessel density. Intimal area and adventitial vessel count were correlated positively. Neointima reduction after intracoronary radiation may depend not only on an antiproliferative effect but also on an anti-angiogenic effect.
Collapse
Affiliation(s)
- M Kollum
- Cardiovascular Research Institute, Washington Hospital Center, Washington, DC, USA
| | | | | | | | | | | | | |
Collapse
|
38
|
Scott NA, Crocker IR, Yin Q, Sorescu D, Wilcox JN, Griendling KK. Inhibition of vascular cell growth by X-ray irradiation: comparison with gamma radiation and mechanism of action. Int J Radiat Oncol Biol Phys 2001; 50:485-93. [PMID: 11380238 DOI: 10.1016/s0360-3016(01)01526-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
PURPOSE Catheter-based delivery of gamma and beta radiation effectively inhibits restenosis. Major disadvantages of these radioisotopes include continuous emission; excessive depth of penetration, creating safety hazards (gamma); and inadequate penetration, limiting effectiveness (beta). Low-voltage X-rays have a distinct potential advantage, because the source is active only when current is applied, and depth of penetration is voltage dependent. This study was performed to determine if low-voltage X-rays inhibit smooth muscle and adventitial cell growth in vitro and to determine the molecular mechanisms involved in this cellular response. METHODS AND RESULTS Vascular cells in culture were exposed to low-voltage X-ray radiation and analyzed for their subsequent ability to proliferate. X-ray irradiation caused a dose-dependent inhibition in proliferation, similar to the effect seen with equivalent doses of gamma radiation. The radiation-induced inhibition of proliferation did not appear to be related to apoptosis, but rather to delayed progression through the cell cycle, because a 65% increase in the proportion of cells in S phase was seen 24-96 h after X-ray exposure compared to control. Expression of p53, a cell cycle transcriptional activator, and p21, a cell cycle inhibitor, were significantly elevated after exposure to low-voltage X-rays, providing a potential mechanism for this delay. CONCLUSIONS Low-voltage X-rays can effectively inhibit proliferation of vascular smooth muscle and adventitial cells. This inhibition is apparently due to a delay in progression through the cell cycle, which is mediated by increases in the levels of cell cycle inhibitors.
Collapse
MESH Headings
- Animals
- Aorta, Thoracic/cytology
- Apoptosis/radiation effects
- Cell Division/radiation effects
- Cells, Cultured
- Coronary Vessels/cytology
- Cyclin-Dependent Kinase Inhibitor p21
- Cyclins/biosynthesis
- Dose-Response Relationship, Radiation
- Gamma Rays
- Humans
- Male
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/radiation effects
- Rats
- Rats, Sprague-Dawley
- Swine
- Tumor Suppressor Protein p53/biosynthesis
- X-Rays
Collapse
Affiliation(s)
- N A Scott
- Department of Medicine, Emory University, Atlanta, GA 30322, USA
| | | | | | | | | | | |
Collapse
|
39
|
Boeing N, Geoghegan S, Ebert MA. Endovascular brachytherapy: dosimetry and dose-area analysis of various radiation sources. AUSTRALASIAN PHYSICAL & ENGINEERING SCIENCES IN MEDICINE 2001; 24:63-70. [PMID: 11560172 DOI: 10.1007/bf03178348] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
With the increase in popularity of endovascular brachytherapy for prevention of restenosis following coronary angioplasty, it remains to be determined which isotope and isotope form is the most ideal. An issue concerning the use of wire sources is the influence of the centering of the wire on dose uniformity across the artery wall and the potential problems this can lead to in terms of underdosage of the target tissues. In this investigation, the dosimetric characteristics of three currently used sources (gamma-emitting 192Ir wire; beta-emitting 32P wire; and beta-emitting 188Re solution) were determined with EGS4 Monte Carlo. The dose results were then used to determine the dose-area relationships for the three sources in arteries with concentric and non-concentric lumens/walls, including situations in which the wire sources are moved away from the centre of the artery. It is found that, in order to ensure dose uniformity, centering is substantially more important for beta-emitting wire sources. This is highlighted most significantly in the case of an example large irregular artery. Although the suitability of a source depends on many criteria (e.g., cost, availability, radiation protection, possible radiation-induced late effects), the problem of centering a wire source in possibly large and/or irregular arteries is greatly eased by the use of a gamma-emitting source.
Collapse
Affiliation(s)
- N Boeing
- Department of Physics, University of Western Australia
| | | | | |
Collapse
|
40
|
Costa MA, Kozuma K, Serruys PW. Why and how to avoid stenting during brachytherapy. INTERNATIONAL JOURNAL OF CARDIOVASCULAR INTERVENTIONS 2001; 4:77-82. [PMID: 12036475 DOI: 10.1080/146288401753258420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Intracoronary radiation is a promising therapy to reduce restenosis after percutaneous coronary intervention. It may be anticipated that radiation and intracoronary stents - the current standard coronary revascularization procedure - have a synergic antirestenosis effect. However, this potential benefit has not been proven in the clinical scenario. Indeed, this combined approach (stenting plus brachytherapy) may even be harmful. Delayed endothelialization and late stent malapposition are important drawbacks of implanting a metallic prosthesis in the setting of radiation therapy. Owing to the relatively high frequency of late thrombosis after stenting irradiated coronary arteries, the Food and Drug Administration required that the labeling of both gamma- and beta-radiation devices recently approved for clinical use explicitly advise avoidance of the placement of new stents. The pathophysiologic aspects as well as the clinical implications of the implantation of a new stent in association with radiation delivered by radioactive stents or catheter-based systems are discussed in this paper.
Collapse
Affiliation(s)
- Marco A Costa
- Division of Cardiology, University of Florida, Florida, USA
| | | | | |
Collapse
|
41
|
Gruberg L, Waksman R. Intravascular radiation for the prevention of recurrence of restenosis in coronary arteries. Expert Opin Investig Drugs 2001; 10:891-907. [PMID: 11322864 DOI: 10.1517/13543784.10.5.891] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Despite the use of new technology and adjunctive pharmacological therapy, in-stent restenosis continues to hamper the outcome of approximately 150,000 patients who undergo stented coronary angioplasty in the US annually. While coronary stenting eliminates elastic recoil and vessel contracture by acting as a mechanical scaffold within the vessel, it is unable to inhibit excessive neointimal formation and may actually promote it. For years, the growth-inhibiting properties of ionising radiation have been used successfully to control benign proliferative disorders. Based on this experience, vascular brachytherapy, the intravascular delivery of radiation, was viewed as a viable solution to inhibit neointimal hyperplasia. A series of studies performed in animal models identified the mechanisms by which radiation may reduce restenosis. Data from these studies showed that endovascular radiation reduces restenosis by inhibiting cell proliferation and by inducing favourable remodelling. The success of these initial studies led to several double-blind, multicentre, placebo-controlled, randomised, clinical trials evaluating intravascular radiation, with either gamma- or beta-radiation sources, proved to be an effective solution for the prevention of neointimal proliferation and restenosis. However, an increased rate of late thrombosis in patients who had received intracoronary radiation did evolve from the initial use of this therapy. Prolonged antiplatelet therapy and a reduction in the number of new stents placed at the time of radiation has been shown to minimise these complications. Other concerns that still need to be resolved include edge effect and geographical miss. Intravascular brachytherapy is currently the only approved therapy for this complex disease. It is clear that there are still on-going concerns that will eventually be clarified when the long-term results from ongoing clinical trials around the world become available.
Collapse
Affiliation(s)
- L Gruberg
- Cardiac Catheterization Laboratory, Cardiovascular Research Institute, Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington, DC 20010, USA.
| | | |
Collapse
|
42
|
Kałuza GL, Raizner AE, Mazur W, Schulz DG, Buergler JM, Fajardo LF, Tio FO, Ali NM. Long-term effects of intracoronary beta-radiation in balloon- and stent-injured porcine coronary arteries. Circulation 2001; 103:2108-13. [PMID: 11319203 DOI: 10.1161/01.cir.103.16.2108] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The data on the long-term safety and efficacy of intracoronary beta-radiation in animal models are limited. METHODS AND RESULTS A total of 30 coronary arteries in 15 swine were subjected to balloon or stent injury followed by beta-radiation from a centered 32P source (2000 cGy to 1 mm beyond lumen surface) or a sham radiation procedure. The animals received aspirin for 6 months and ticlopidine for 30 days. Five of the 10 animals subjected to radiation died (at 5 days, 7 days, 3 months [n = 2], and 4 months) as a result of layered, occlusive thrombus at the intervention site (3 stent and 2 balloon injury sites). No deaths occurred in the control group. In the surviving animals, balloon-injured and irradiated vessels showed a trend toward larger lumens than controls (2.15 +/- 0.17 versus 1.80 +/- 0.08 mm2, P=0.06) and larger external elastic lamina areas (3.32 +/- 0.21 versus 2.62 +/- 0.10 mm2, P=0.003). In the stent-injured vessels from surviving animals, lumen, neointimal, and external elastic lamina areas were 3.58 +/- 0.33, 3.16 +/- 0.35, and 8.12 +/- 0.42 mm2 for irradiated vessel segments; these values were not different from those in controls (3.21 +/- 0.15, 2.84 +/- 0.27, and 7.76 +/- 0.28 mm2, respectively). Histologically, healing was complete in most survivors, although intramural fibrin and hemorrhage were occasionally seen. CONCLUSION In the long-term (6 month) porcine model of restenosis, the inhibition by intracoronary beta-radiotherapy of the neointimal formation that is known to be present at 1 month is not sustained. This lack of effect on neointimal formation after balloon and stent arterial injury is accompanied by subacute and late thrombosis that leads to cardiac death on a background of continuous aspirin but relatively brief ticlopidine treatment.
Collapse
Affiliation(s)
- G L Kałuza
- Department of Medicine, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Waksman R, Bhargava B, Chan RC, Sherman W, Pisch J, Mintz GS, Lansky AJ, Ahmed J, Ricci NA, Liprie SF. Intracoronary radiation with gamma wire inhibits recurrent in-stent restenosis. CARDIOVASCULAR RADIATION MEDICINE 2001; 2:63-8. [PMID: 11340009 DOI: 10.1016/s1522-1865(00)00086-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
To study the safety and efficacy of intracoronary gamma radiation delivered via a new high-activity (192)Ir source wire for the treatment of in-stent restenosis. In-stent restenosis results from neointimal tissue proliferation especially in its diffused form and presents a therapeutic challenge. Gamma radiation has been shown to decrease neointima formation within stents in animal models and in initial clinical trials. A total of 26 patients with in-stent restenosis underwent successful intervention and was treated with open-label (192)Ir using a high-activity line source. The specific activity of the source wire was 372+/-51 mCi, and the dwell time was 10.8+/-1.9 min. Primary endpoints were freedom from death, myocardial infraction (MI), and repeat target lesion revascularization (TLR) at 6 months. Secondary endpoints included angiographic restenosis and intravascular ultrasound (IVUS) neointimal hyperplasia. Procedural success was high (96.2%), and in-hospital and 30-day complications were low with no deaths, MI, or requirement for repeat revascularization. At 6 months, event-free survival was 85%: one patient required repeat PTCA, one underwent bypass surgery, and two had an MI. Baseline lesion length measured 15.77 mm. Follow-up angiography was available in 21/25 (84%) patients. The binary restenosis rates were 19.0% (4/21) in-stent and 23.8% (5/21) in-lesion. Follow-up IVUS was available in 20/25 patients. There was no increase in intimal hyperplasia from postintervention to follow-up (3.11.8 vs. 3.41.8 mm(2); P=.32). Eight patients had a reduction of neointimal intimal tissue at follow-up. These results indicate that intracoronary gamma radiation with the Angiorad source wire is safe and effective in preventing in-stent restenosis.
Collapse
Affiliation(s)
- R Waksman
- Washington Hospital Center, 110 Irving Street North West, Suite 4B-1, Washington, DC 20010, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Kałuza GL, Mazur W, Raizner AE. Basic science review: radiotherapy for prevention of restenosis. Catheter Cardiovasc Interv 2001; 52:518-29. [PMID: 11285612 DOI: 10.1002/ccd.1115] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- G L Kałuza
- Methodist DeBakey Heart Center, Houston, Texas 77030, USA
| | | | | |
Collapse
|
45
|
Levesque L, Lam MH, Allaire P, Mondat M, Houle S, Beaudoin G, Donath D, Leclerc G. Effects of radiation therapy on vascular responsiveness. J Cardiovasc Pharmacol 2001; 37:381-93. [PMID: 11300651 DOI: 10.1097/00005344-200104000-00005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The use of radiation therapy to inhibit vascular proliferative diseases has produced encouraging results in several clinical trials. However, little is known about the possible side effects of radiation on vascular responsiveness. Our goal was to study the in vitro vascular responses of the rabbit aorta to various agonists immediately after several regimens of radiation therapy administered at doses prescribed in clinical protocols and at two different dose rates. High-dose-rate radiation was administered either by brachytherapy, using a gamma source, iridium 192, or an external electron beam producing beta radiation. Low-dose-rate radiation was administered by brachytherapy using a liquid-filled balloon with the beta emitter 32P. Vascular reactivity after the various regimens of irradiation was determined using the organ bath pharmacology assay. Various agonists were applied to the rabbit aorta to produce full cumulative concentration-response curves. Radiation, administered using an external electron beam, did not alter endothelium-dependent relaxation of the aorta induced by acetylcholine. However, the use of a catheter-based system to deliver radiation disrupted the endothelial cell lining of the vessel, causing a lack of relaxation by acetylcholine. Therefore, to compare all modalities of radiation therapy on vascular responsiveness, the agonists used in this study are known to act directly on the smooth muscle. Radiation therapy had no effect on the contractile responses induced by the following agonists: phenylephrine and potassium chloride. Vascular dilatation induced by nitroglycerin, a nitric oxide donor, was unaffected by radiation therapy. The contractile response induced by des-Arg9-bradykinin, a kinin B1 receptor agonist, was significantly increased twofold to threefold by all types of irradiation under study. This enhanced response is attributable to an increase of mRNA levels coding for this receptor. In all cases, radiation therapy did not alter the effective concentration producing 50% of maximal responsiveness (EC50) and did not reduce the vascular responsiveness induced by agonists. Taken together, we conclude that radiation therapy does not hinder endothelium-independent vascular responsiveness and increases the kinin B1 receptor-mediated vasoconstriction.
Collapse
Affiliation(s)
- L Levesque
- Laboratory of Molecular Cardiology, Centre Hospitalier de l'Université de Montréal, Quebec, Canada
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Kaluza GL, Zymek PT, Raizner AE. Prevention of restenosis with intravascular beta-radiotherapy. Curr Atheroscler Rep 2001; 3:169-73. [PMID: 11177662 DOI: 10.1007/s11883-001-0054-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Beta radiation has been clearly shown, in a specific dose range, to be highly effective in the inhibition of the restenotic process after balloon or stent injury in animal experiments, as well as in randomized, placebo-controlled human trials. The major advantage of beta radiation, in comparison with gamma radiation, is a significantly lower radiation exposure to the personnel and patient, and easier adaptability to existing cardiac catheterization laboratories. Rapidly accumulating evidence indicates that the two major problems, late thrombosis and edge stenosis, may be minimized with prolonged antiplatelet therapy (6 months or more) and broader radiation coverage of the intervention site. Although there may be better, safer, and easier options to reduce restenosis in the years to come, intravascular radiotherapy is the first breakthrough modality that has been shown to significantly reduce restenosis after percutaneous vascular interventions.
Collapse
Affiliation(s)
- G L Kaluza
- The Methodist DeBakey Heart Center and Section of Cardiology, Department of Medicine, Baylor College of Medicine, 6535 Fannin, Room FB 1034, Houston, TX 77030, USA
| | | | | |
Collapse
|
47
|
Waksman R, Bhargava B, Saucedo JF, Chan RC, Tio FO, Vodovotz Y, Verin V. Yttrium-90 delivered via a centering catheter and afterloader, given both before and after stent implantation, inhibits neointima formation in porcine coronary arteries. ACTA ACUST UNITED AC 2001. [DOI: 10.1016/s1522-1865(00)00043-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
48
|
Qu X, Weinberger J. Novel beta-emitting poly(ethylene terephthalate) surface modification. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH 2000; 52:492-7. [PMID: 11007617 DOI: 10.1002/1097-4636(20001205)52:3<492::aid-jbm7>3.0.co;2-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Restenosis after percutaneous interventions in coronary and peripheral arteries leads to repeat procedures and surgery in a significant number of patients. We have previously demonstrated that irradiation of an arterial site using an endovascular source (brachytherapy) is highly effective in preventing the restenotic process. To this end, a novel beta radiation delivery system was developed, based on the adsorption of (32)P (o-phosphoric acid) by pH-sensitive chitosan hydrogel on a poly(ethylene terephthalate) (PET) balloon surface. The PET balloon surface was treated with oxygen plasma and coated with chitosan hydrogel. Covalent bonds, ionic bonds, and hydrogen bonds all contribute to the adhesion between chitosan hydrogel and PET. In the aqueous phosphoric acid (PA) solution, the -NH(2) groups of chitosan were protonated by PA and the adsorption of PA occurred at the same time. The effect of PA concentration and temperature on adsorption efficiency and kinetics were studied. More than 70% PA was adsorbed on the sample surface in 0.2 mM PA solution. The surface of samples was also investigated by attenuated total reflection-Fourier transform infrared spectroscopy and scanning electron microscopy. PET surface may be modified to carry high activity beta emitters; such materials may be useful in a therapeutic setting
Collapse
Affiliation(s)
- X Qu
- Interventional Cardiology Center, Departments of Medicine and Pharmacology, Columbia University, 161 Fort Washington Avenue, AP-551, New York, New York 10032, USA
| | | |
Collapse
|
49
|
Kaluza GL, Ali NM, Raizner AE. Intracoronary radiotherapy for prevention of restenosis after percutaneous coronary interventions. Ann Med 2000; 32:622-31. [PMID: 11209970 DOI: 10.3109/07853890009002033] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
More than 50 different pharmacological and mechanical interventions have been tested to date for prevention of vascular restenosis without success. Intracoronary radiotherapy is the first one showing promise of significantly attenuating neointimal proliferation, causing positive vascular remodelling and thus inhibiting restenosis. This promising modality has moved from animal experiments via safety and feasibility testing into the phase of clinical trials of efficacy in large numbers of patients. While ongoing research continues to search for new sources and delivery techniques, currently available technology is being optimized. The randomized clinical trials conducted to date have shown consistently a reduction of target site restenosis rates by 55-79%. Lower incidence of major adverse cardiac events after radiotherapy has also been demonstrated, primarily as a result of reduction in target site and target vessel revascularization rates. However, experimental and clinical research has identified two major complications of this approach: stenosis at the ends of the radiation zone ('edge effect' or 'candywrapper') as well as late thrombosis (beyond 30 days after intervention) of the angioplasty or stent site. If these two adverse effects can be minimized, intracoronary radiotherapy may prove to be a major breakthrough in percutaneous coronary interventions.
Collapse
Affiliation(s)
- G L Kaluza
- The Methodist Hospital and Baylor College of Medicine, Houston, TX 77030, USA
| | | | | |
Collapse
|
50
|
Ishiwata S, Robinson K, Chronos N, Crocker IR, King SB. Irradiation and postangioplasty restenosis: a recent overview. JAPANESE HEART JOURNAL 2000; 41:541-70. [PMID: 11132163 DOI: 10.1536/jhj.41.541] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
One of the most intriguing developments in recent years towards prevention of restenosis after angioplasty is the use of ionizing radiation. The background for the use of radiation treatment for this application is sound, since radiation is used not only to treat malignant cancerous growths but also is used for treatment of benign hyperplastic disorders such as post-surgical keloid formation and recurrence of pterygium after surgical removal. Restenosis can be considered a form of overexuberant wound healing triggered by angioplasty. Ionizing radiation inhibits serum-stimulated proliferation of many cell types including fibroblasts and smooth muscle cells in vitro and also suppresses the synthesis of collagen by cultured fibroblasts. Liermann who showed inhibition of post-stent restenosis first used ionizing radiation for restenosis prevention clinically in iliac and iliofemoral arteries. Subsequently, extensive animal studies in various restenosis models have shown a profound inhibitory effect of catheter-based radiation (endovascular brachytherapy) on neointima formation and overall vessel shrinkage (negative remodeling). Based on these results clinical trials have been initiated with several types of devices and isotopes. Among these are 192Ir, 32P, 90Y, 90Sr/Y and 188Re. Additionally, radioactive stents have been developed; devices for clinical use are made radioactive at the microCi level by surface implantation of 32P ions. Results from early clinical trials are encouraging and brachytherapy appears safe for clinical use and at an appropriate dose, may be highly effective for restenosis prevention.
Collapse
Affiliation(s)
- S Ishiwata
- Cardiovascular Center, Toranomon Hospital, Tokyo, Japan
| | | | | | | | | |
Collapse
|